Penetration of polymeric nanoparticles loaded with an HIV-1 inhibitor peptide derived from GB virus C in a vaginal mucosa model

dc.contributor.authorAriza Sáenz, Martha Rocío
dc.contributor.authorEspina García, Marta
dc.contributor.authorBolaños, Núria
dc.contributor.authorCalpena Campmany, Ana Cristina
dc.contributor.authorGomara, Maria José
dc.contributor.authorHaro, Isabel
dc.contributor.authorGarcía López, María Luisa
dc.date.accessioned2018-07-04T13:17:50Z
dc.date.available2018-12-31T06:10:25Z
dc.date.issued2017-11
dc.date.updated2018-07-04T13:17:51Z
dc.description.abstractDespite the great effort to decrease the HIV infectivity rate, current antiretroviral therapy has several weaknesses; poor bioavailability, development of drug resistance and poor ability to access tissues. However, molecules such as peptides have emerged as a new expectative to HIV eradication. The vaginal mucosa is the main spreading point of HIV. There are natural barriers such as the vaginal fluid which protects the vaginal epithelium from any foreign agents reaching it. This work has developed and characterized Nanoparticles (NPs) coated with glycol chitosan (GC), loaded with an HIV-1 inhibitor peptide (E2). In vitro release and ex vivo studies were carried out using the vaginal mucosa of swine and the peptide was determined by HPLC MS/MS validated method. Moreover, the peptide was labeled with 5(6)-carboxyfluoresceine and entrapped into the NPs to carried out in vivo studies and to evaluate the NPs penetration and toxicity in the vaginal mucosa of the swine. The mean size of the NPs, ξ and the loading percentage were fundamental features for to reach the vaginal tissue and to release the peptide within intercellular space. The obtained results suggesting that the fusion inhibitor peptides loaded into the NPs coated with GC might be a new way to fight the HIV-1, due to the formulation might reach the human epithelial mucosa and release peptide without any side effects.
dc.format.extent28 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec673740
dc.identifier.issn0939-6411
dc.identifier.pmid28842284
dc.identifier.urihttps://hdl.handle.net/2445/123357
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.ejpb.2017.08.008
dc.relation.ispartofEuropean Journal of Pharmaceutics and Biopharmaceutics, 2017, vol. 120, p. 98-106
dc.relation.urihttps://doi.org/10.1016/j.ejpb.2017.08.008
dc.rightscc-by-nc-nd (c) Elsevier B.V., 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationNanopartícules
dc.subject.classificationPèptids
dc.subject.classificationSistemes d'alliberament de medicaments
dc.subject.classificationVagina
dc.subject.classificationMembrana mucosa
dc.subject.otherNanoparticles
dc.subject.otherPeptides
dc.subject.otherDrug delivery systems
dc.subject.otherVagina
dc.subject.otherMucous membrane
dc.titlePenetration of polymeric nanoparticles loaded with an HIV-1 inhibitor peptide derived from GB virus C in a vaginal mucosa model
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
673740.pdf
Mida:
18.56 MB
Format:
Adobe Portable Document Format